Journal article icon

Journal article

Assessment of EGFR/HER2 dimerization by FRET-FLIM utilizing Alexa-conjugated secondary antibodies in relation to targeted therapies in cancers.

Abstract:

The expression level of the HER family is unreliable as a predictive marker for targeted therapies in cancer. Thus, there is a need to develop other biomarkers, which can be used to accurately select responsive patients for targeted therapies. The HER dimerization status may be more important than HER receptor expression per se in determining sensitivity or resistance to a given therapeutic agent. The aim of the study is to develop a FRET assay using dye conjugated secondary antibodies to ass...

Expand abstract
Publication status:
Published

Actions


Authors


Waterhouse, BR More by this author
Barber, PR More by this author
Tullis, ID More by this author
More by this author
Institution:
University of Oxford
Department:
Oxford, MSD, Oncology
Expand authors...
Journal:
Oncotarget
Volume:
2
Issue:
9
Pages:
728-736
Publication date:
2011-09-05
EISSN:
1949-2553
ISSN:
1949-2553
URN:
uuid:24fe5cb6-d1fd-473c-badb-760f11aa79aa
Source identifiers:
175208
Local pid:
pubs:175208

Terms of use


Metrics



If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP